Literature DB >> 26882482

The Problem of Mammographic Breast Density - The Position of the DEGUM Working Group on Breast Ultrasound.

M P Mueller-Schimpfle1, V C Brandenbusch2, F Degenhardt3, V Duda4, H Madjar5, A Mundinger6, R Rathmann7, M Hahn8.   

Abstract

Mammographic breast density correlates with breast cancer risk and also with the number of false-negative calls. In the USA these facts lead to the "Breast Density and Mammography Reporting Act" of 2011. In the case of mammographically dense breasts, the Working Group on Breast Ultrasound in Germany recommends explaining the advantages of adjunct imaging to women, depending on the individual breast cancer risk. Due to the particular structure of German healthcare, quality-assured breast ultrasound would be the first choice. Possible overdiagnosis, costs, potentially increased emotional stress should be addressed. In high familial breast cancer risk, genetic counselling and an intensified early detection program should be performed. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2016        PMID: 26882482     DOI: 10.1055/s-0041-108004

Source DB:  PubMed          Journal:  Ultraschall Med        ISSN: 0172-4614            Impact factor:   6.548


  3 in total

Review 1.  [Diagnosis of breast diseases in a certified breast center].

Authors:  Markus Müller-Schimpfle; Nicole Herröder; Petra Hödl
Journal:  Radiologe       Date:  2021-01-06       Impact factor: 0.635

2.  Synergy in combining findings from mammography and ultrasonography in detecting malignancy in women with higher density breasts and lesions over 2 cm in Albania.

Authors:  Altin Malaj; Albana Shahini
Journal:  Contemp Oncol (Pozn)       Date:  2017-01-12

3.  Analysis of the causes of false negative and false positive results of preoperative axillary ultrasound in patients with early breast cancer - a single-centre study.

Authors:  Tomasz Nowikiewicz; Adam Nowak; Magdalena Wiśniewska; Michał Wiśniewski; Magdalena Nowikiewicz; Wojciech Zegarski
Journal:  Contemp Oncol (Pozn)       Date:  2018-12-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.